Kura Oncology's Ziftomenib Shows Strong Frontline AML Data, Phase 3 Trial Enrollment Underway

Event summary

  • Kura Oncology and Kyowa Kirin will present updated Phase 1 trial data for ziftomenib in combination with 7+3 chemotherapy at EHA 2026 Congress.
  • The dataset includes 99 patients with newly diagnosed NPM1-mutant or KMT2A-rearranged AML, showing CRc rates of 90–96% and MRD negativity rates above 80%.
  • Median duration of CRc not reached in NPM1-m patients at ~15 months median follow-up.
  • Phase 3 KOMET-017 trial is currently enrolling, with potential for accelerated FDA review in 2028.

The big picture

Kura Oncology's updated data for ziftomenib in combination with intensive chemotherapy represents a significant step in the frontline treatment of genetically defined AML subsets. The high response rates and deep molecular responses highlight the potential of menin inhibitors in precision oncology. The ongoing Phase 3 trial and potential accelerated FDA review could position ziftomenib as a key player in the AML treatment landscape, pending successful trial outcomes and regulatory approvals.

What we're watching

Regulatory Pathway
Whether the Phase 3 KOMET-017 trial data will support an accelerated FDA review in 2028.
Market Positioning
How Kura Oncology positions ziftomenib as a foundational backbone for frontline AML therapy against competitors.
Clinical Efficacy
The durability of responses in the longer-term follow-up data presented at EHA 2026.

Related topics

Oncology